Trial Profile
Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Andrographolide (Primary)
- Indications Multiple sclerosis
- Focus Proof of concept; Therapeutic Use
- Sponsors InnoBioscience
- 12 Oct 2018 Results (n=43) assessing Efficacy, safety and tolerability of Andrographolide presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 29 Mar 2018 New trial record